Global Assets Advisory LLC raised its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 167.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,420 shares of the conglomerate’s stock after purchasing an additional 2,768 shares during the period. Global Assets Advisory LLC’s holdings in Danaher were worth $889,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Invesco Ltd. increased its position in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Danaher by 4.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.20% of the stock is currently owned by insiders.
Danaher Stock Performance
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is currently 27.23%.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the company. Bank of America lowered their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Royal Bank Of Canada set a $241.00 price target on Danaher in a report on Tuesday, September 2nd. Robert W. Baird lifted their price objective on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Finally, Guggenheim reissued a “buy” rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.91.
Check Out Our Latest Analysis on DHR
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- How to Short Nasdaq: An Easy-to-Follow Guide
- 3 Defense Stocks Surging as Ukraine Tensions Deepen
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Starbucks Stock Slumps; This Competitor Shows Strength
- Canada Bond Market Holiday: How to Invest and Trade
- The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.